In an effort to combat the off-label use of its anticancer drug Avastin (bevacizumab) in the treatment of wet age-related macular degeneration, US biotechnology major Genentech says it will stop supplying the product to certain retailers.
Avastin, which is approved by the US Food and Drug Administration in a variety of cancer indications (Marketletters passim), is chemically similar to the wet-AMD treatment Lucentis (ranibizumab) that Genentech developed in collaboration with Swiss major Novartis. As a result, compounding pharmacies, which are licensed to mix and repackage drugs, have been providing Avastin in monthly single-dose formulations for around $40, a fraction of the $2,000 per month cost of Lucentis.
In a letter to physicians, Genentech's president of product development, Susan Desmond-Hellmann, said that the firm would no longer allow compounding pharmacies to buy Avastin direct from wholesale distributors. She added that the change would go into effect on November 30, to allow physicians and pharmacists time to adjust.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze